Related Experiment Video

Updated: Mar 22, 2026

Personalized Peptide Arrays for Detection of HLA Alloantibodies in Organ Transplantation
08:07

Personalized Peptide Arrays for Detection of HLA Alloantibodies in Organ Transplantation

Published on: September 6, 2017

10.7K

Association between the HLA-DQB1 polymorphisms and the susceptibility of chronic hepatitis B: A comprehensive

Jinmei Huang1, Liangshi Xiong1, Jin Wang1

  • 1Department of Infectious Disease, The Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, P.R. China.

Biomedical Reports
|April 29, 2016
PubMed

Insights

Human leukocyte antigen (HLA)-DQB1 gene variations influence chronic hepatitis B (CHB) risk. Specific HLA-DQB1 polymorphisms increase CHB susceptibility, while others offer protection, impacting disease development.

Area of Science:

  • Immunogenetics
  • Hepatology
  • Genomics

Background:

  • Single-nucleotide polymorphisms (SNPs) in the human leukocyte antigen (HLA)-DQB1 gene are linked to chronic inflammatory and immunological diseases.
  • Host genetic factors play a crucial role in the pathogenesis of chronic hepatitis B (CHB).

Purpose of the Study:

  • To investigate the association between HLA-DQB1 gene polymorphisms and susceptibility to chronic hepatitis B.

Main Methods:

  • A meta-analysis was conducted, pooling data from 7 case-control studies involving 815 CHB patients and 731 controls.
  • Searched PubMed, Embase, CNKI, and Wanfang databases for relevant studies published between January 1, 1966, and July 30, 2015.
  • Analyzed HLA-DQB1 polymorphism-specific odds ratios (OR) and 95% confidence intervals (95% CI) using a fixed-effects model.
  • Assessed heterogeneity using Q-test and I² statistics, and publication bias using Begg's funnel and Egger's tests.

Main Results:

  • HLA-DQB1 polymorphisms *0201, *0301, and *0502 were significantly associated with an increased risk of CHB (ORs ranging from 1.29 to 1.50).
  • HLA-DQB1 polymorphisms *0303 and *0604 were associated with a decreased risk of CHB (ORs of 0.77 and 0.38, respectively).
  • No significant association was found for other HLA-DQB1 family loci.

Conclusions:

  • Specific HLA-DQB1 polymorphisms (*0201, *0301, *0502) are linked to a higher susceptibility to CHB.
  • Conversely, HLA-DQB1 polymorphisms (*0303, *0604) appear to confer a protective effect against CHB.
  • These findings support the role of HLA-DQB1 allele variations in determining individual susceptibility or resistance to CHB.

Keywords:
chronic hepatitis Bhuman leukocyte antigen haplotypeshuman leukocyte antigens/allelesmeta-analysis

More Related Videos

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix10:37

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

3.5K
Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection04:11

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

5.1K

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
27
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
106
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
16.5K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
65
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
159
Genetic Lingo01:11

Genetic Lingo

Overview
117.1K